- Home
- CABA vs YDDL Comparison
CABA vs YDDL Comparison
Compare CABA & YDDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- YDDL
- Stock Information
- Founded
- CABA 2017
- YDDL 2014
- Country
- CABA United States
- YDDL Philippines
- Employees
- CABA N/A
- YDDL N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- YDDL Industrial Specialties
- Sector
- CABA Health Care
- YDDL Consumer Discretionary
- Exchange
- CABA Nasdaq
- YDDL Nasdaq
- Market Cap
- CABA 260.7M
- YDDL 295.4M
- IPO Year
- CABA 2019
- YDDL 2025
- Fundamental
- Price
- CABA $2.45
- YDDL $5.09
- Analyst Decision
- CABA Strong Buy
- YDDL
- Analyst Count
- CABA 8
- YDDL 0
- Target Price
- CABA $11.63
- YDDL N/A
- AVG Volume (30 Days)
- CABA 5.1M
- YDDL 2.1M
- Earning Date
- CABA 11-13-2025
- YDDL 11-25-2025
- Dividend Yield
- CABA N/A
- YDDL N/A
- EPS Growth
- CABA N/A
- YDDL 16.34
- EPS
- CABA N/A
- YDDL 0.12
- Revenue
- CABA N/A
- YDDL $53,463,785.00
- Revenue This Year
- CABA N/A
- YDDL N/A
- Revenue Next Year
- CABA N/A
- YDDL N/A
- P/E Ratio
- CABA N/A
- YDDL $38.14
- Revenue Growth
- CABA N/A
- YDDL 29.55
- 52 Week Low
- CABA $0.99
- YDDL $4.00
- 52 Week High
- CABA $5.46
- YDDL $8.89
- Technical
- Relative Strength Index (RSI)
- CABA 50.01
- YDDL N/A
- Support Level
- CABA $2.77
- YDDL N/A
- Resistance Level
- CABA $3.01
- YDDL N/A
- Average True Range (ATR)
- CABA 0.37
- YDDL 0.00
- MACD
- CABA -0.03
- YDDL 0.00
- Stochastic Oscillator
- CABA 19.36
- YDDL 0.00
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.